Friday, 16 October 2026European Markets

SOCIETE GENERALE Stock Impressive Slide 11% So Far On Wednesday, Underperforms Market

Loading stream...

(vianews) - shares of societe generale (cac 40: gle.pa) fell by a staggering 11.99% to €21.54 at 13:07 est on wednesday, after two sequential sessions in a row of losses. cac 40 is dropping 3.4% to €6,898.42, following the last session's upward trend. this seems, as yet, a very negative trend trading session today.

societe generale's last close was €25.52, 10.11% under its 52-week high of €28.39.

about societe generale

société générale société anonyme provides banking and financial services to individuals, businesses, and institutional investors in europe and internationally. it operates through three segments: retail banking in france, international retail banking and financial services, and global banking and investor solutions. it offers retail banking services, such as consumer credit, vehicle leasing and fleet management, financing of professional equipment, and long-term leasing activities under the societe generale, credit du nord, and boursorama brand names; and insurance products, including home, vehicle, family, health, and mortgage insurance. the company also provides corporate and investment banking, securities, market and investor, financing and consulting, and asset management and private banking services. in addition, it offers security brokerage, equipment finance, cash management, payment services, factoring, and supply chain financing services. société générale société anonyme was founded in 1864 and is based in paris, france.

earnings per share

as for profitability, societe generale has a trailing twelve months eps of €-1.02.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.1%.

yearly top and bottom value

societe generale's stock is valued at €21.54 at 13:07 est, way below its 52-week high of €28.39 and way higher than its 52-week low of €18.97.

more news about societe generale (gle.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com